

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

PATENT
Attorney Docket No.: 018781-005710US
Client Reference No.: T00-007-1

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

On 7/11/03

TOWNSEND and TOWNSEND and CREW LLP

By: Jennifer K. Handi



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Michelle BROWNER *et al.*

Application No.: 10/004,287

Filed: October 23, 2001

For: ANTIINFLAMMATION AGENTS

Examiner: Balasubramanian, V.

Art Unit: 1624

INFORMATION DISCLOSURE
STATEMENT UNDER 37 CFR §1.97 and
§1.98

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

The references cited on attached form PTO/SB/08A and PTO/SB/08B are being called to the attention of the Examiner. Copies of the references are enclosed.

It is respectfully requested that the cited references be expressly considered during the prosecution of this application, and the references be made of record therein and appear among the "references cited" on any patent to issue therefrom.


As provided for by 37 CFR 1.97(g) and (h), no inference should be made that the information and references cited are prior art merely because they are in this statement and no representation is being made that a search has been conducted or that this statement encompasses all the possible relevant information.

MAR 03 2004

This IDS is being filed before the mailing date of the final Office Action or
Notice of Allowance.

Please charge the IDS fee of \$180 to Deposit Account No. 20-1430. Please
deduct any additional fees from, or credit any overpayment to, the above-noted Deposit Account.

Respectfully submitted,


William B. Kezer
Reg. No. 37,369

TOWNSEND and TOWNSEND and CREW LLP
Two Embarcadero Center, 8th Floor
San Francisco, California 94111-3834
Tel: 925-472-5000
Fax: 925-472-8895

WBK:ath

WC 9060892 v1



PTO/SB/08A (04-03)

Approved for use through 04/30/2003. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 1 of 2

Complete If Known

Application Number	10/004,287
Filing Date	October 23, 2001
First Named Inventor	Browner, Michelle F.
Art Unit	1624
Examiner Name	Balasubramanian, V.
Attorney Docket Number	018781-005710US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA	US-6,207,679 B1	03/27/2001	Cuny et al.	
	AB	US-6,258,822	07/10/2001	Geyer et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ²	Number ⁴	Kind Code ⁵ (if known)				
	AC	WO	01/00610	A1	01/04/2001	Aventis Pharma Deutschland GMBH		<input type="checkbox"/>
	AD	WO	01/30774	A1	05/03/2001	Aventis Pharma Deutschland GMBH		<input type="checkbox"/>
	AE	WO	01/58890	A1	08/16/2001	Astrazeneca AB		<input type="checkbox"/>
	AF	WO	01/68648	A1	09/20/2001	Aventis Pharma Deutschland GMBH		<input type="checkbox"/>
	AG	WO	02/24679	A1	03/28/2002	Bayer Aktengesellschaft		<input type="checkbox"/>
	AH	WO	02/28860	A2	04/11/2002	Bristol-Myers Squibb Company		<input type="checkbox"/>
	AI	WO	02/30353	A2	04/18/2002	SmithKline Beecham Corporation		<input type="checkbox"/>
	AJ	WO	02/30423	A1	04/18/2002	SmithKline Beecham Corporation		<input type="checkbox"/>
	AK	WO	02/41843	A2	05/30/2002	Tularik Inc. and F. Hoffmann La Roche AG		<input type="checkbox"/>
	AL	WO	02/44153	A1	06/06/2002	Bayer Aktengesellschaft		<input type="checkbox"/>
	AM	WO	02/46171	A2	06/13/2002	Signal Pharmaceuticals, Inc.		<input type="checkbox"/>
	AN	WO	02/060386	A2	08/08/2002	Bristol-Myers Squibb Company		<input type="checkbox"/>
	AO	WO	02/076985	A1	10/03/2003	SmithKline Beecham Corporation		<input type="checkbox"/>

Examiner
SignatureDate
Considered


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.87 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9060892 v1



PTO/SB/08B (04-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Page 2 of 2

Complete if Known

Application Number	10/004,287
Filing Date	October 23, 2001
First Named Inventor	Browner, Michelle F.
Art Unit	1624
Examiner Name	Balasubramanian, V.
Attorney Docket Number	018781-005710US

NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AP	Karin, M., 1999, "The Beginning of the End: I κ B Kinase (IKK) and NF- κ B Activation," <i>The Journal of Biological Chemistry</i> 274(39):27339-27342	
	AQ	Karin, M., 1999, "How NF- κ B is activated: the role of the I κ B kinase (IKK) complex," <i>Oncogene</i> 18:6867-6874	
	AR	Karin and Delhase, 2000, "The I κ B Kinase (IKK) and NF- κ B: key elements in proinflammatory signaling," <i>Seminars in Immunology</i> 12(1):85-98 (Abstract)	
	AS	May et al., 2000, "Selective inhibition of NF- κ B activation by a peptide that blocks the interaction of NEMO with the I κ B kinase complex," <i>Science</i> 289:1550-1554	
	AT	Rossi et al., 2000, "Anti-inflammatory cyclopentenone prostaglandins are direct inhibitors of I κ B kinase," <i>Nature</i> 403:103-108	
	AU	Woronicz et al., 1997, "I κ B Kinase- β : NF- κ B Activation and Complex Formation with I κ B Kinase- α and NIK," <i>Science</i> 278:866-870	

MAR 09 2004

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

WC 9060892 v1